In its largest 2018 deal to date, Boston Scientific Corp., of Marlborough, Mass., agreed to acquire Bedford, Mass.-based Augmenix Inc., which has developed the SpaceOAR system to reduce the side effects that men may experience after receiving prostate cancer radiotherapy. The deal calls for an upfront cash payment of $500 million, plus up to $100 million for reaching sales-based milestones.